For research use only. Not for therapeutic Use.
Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC50=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence[1].
Catalog Number | I040576 |
CAS Number | 2738583-25-8 |
Synonyms | 2-methyl-1-oxo-4-[[4-(sulfamoylamino)phenyl]methyl]phthalazine |
Molecular Formula | C16H16N4O3S |
Purity | ≥95% |
InChI | InChI=1S/C16H16N4O3S/c1-20-16(21)14-5-3-2-4-13(14)15(18-20)10-11-6-8-12(9-7-11)19-24(17,22)23/h2-9,19H,10H2,1H3,(H2,17,22,23) |
InChIKey | ZBMUKGSKMVACJQ-UHFFFAOYSA-N |
SMILES | CN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)NS(=O)(=O)N |
Reference | [1]. Cho Y et al. Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy. J Med Chem. 2023 Nov 23;66(22):15141-15170. |